Clobex Patent Expiration

Clobex is a drug owned by Galderma Laboratories Inc. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 03, 2022. Details of Clobex's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7700081 Foaming compositions for hair care
Jan, 2022

(2 years ago)

Expired
US8066975 Foaming composition for washing and treating hair and/or scalp based on an active principle
Jun, 2019

(5 years ago)

Expired
US8066976 Foaming compositions for hair care
Jun, 2019

(5 years ago)

Expired
US7316810 Foaming composition for washing and treating hair and/or scalp based on an active principle
Jun, 2019

(5 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Clobex's patents.

Given below is the list of recent legal activities going on the following patents of Clobex.

Activity Date Patent Number
Patent litigations
Expire Patent 01 Jan, 2024 US8066975
Expire Patent 01 Jan, 2024 US8066976
Maintenance Fee Reminder Mailed 17 Jul, 2023 US8066975
Maintenance Fee Reminder Mailed 17 Jul, 2023 US8066976
Expire Patent 23 May, 2022 US7700081
Maintenance Fee Reminder Mailed 06 Dec, 2021 US7700081
Payment of Maintenance Fee, 8th Year, Large Entity 16 May, 2019 US8066975
Payment of Maintenance Fee, 8th Year, Large Entity 16 May, 2019 US8066976
Payment of Maintenance Fee, 8th Year, Large Entity 05 Oct, 2017 US7700081
Patent Issue Date Used in PTA Calculation 29 Nov, 2011 US8066975

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Clobex is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Clobex's family patents as well as insights into ongoing legal events on those patents.

Clobex's Family Patents

Clobex has patent protection in a total of 21 countries. It's US patent count contributes only to 13.8% of its total global patent coverage. 13 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Clobex.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Clobex's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 03, 2022 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Clobex Generics:

Clobetasol Propionate is the generic name for the brand Clobex. 34 different companies have already filed for the generic of Clobex, with Taro having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Clobex's generic

How can I launch a generic of Clobex before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Clobex's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Clobex's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Clobex -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
0.0005 27 Mar, 2006 1 04 Dec, 2008 22 Sep, 2017 Eligible
0.0005 29 Sep, 2008 1 16 Jun, 2011 24 Mar, 2018 Eligible
0.0005 09 Jan, 2008 1 07 Jun, 2011 17 Jun, 2019 Non-Forfeiture

Alternative Brands for Clobex

Clobex which is used for treating scalp psoriasis and moderate to severe plaque psoriasis., has several other brand drugs in the same treatment category and using the same active ingredient (Clobetasol Propionate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Primus Pharms
Impoyz

(uses Clobetasol Propionate)

Used for treating moderate to severe plaque psoriasis in patients 18 years of age or older.

Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Clobetasol Propionate. Given below is the list of those drugs and companies owning them.

Drug Owner Drug Name
Eyenovia
Clobetasol Propionate
Norvium Bioscience
Olux
Olux E


Apart from brand drugs containing the same ingredient, some generics have also been filed for Clobetasol Propionate, Clobex's active ingredient. Check the complete list of approved generic manufacturers for Clobex





About Clobex

Clobex is a drug owned by Galderma Laboratories Inc. It is used for treating scalp psoriasis and moderate to severe plaque psoriasis. Clobex uses Clobetasol Propionate as an active ingredient. Clobex was launched by Galderma Labs in 2004.

Approval Date:

Clobex was approved by FDA for market use on 05 February, 2004.

Active Ingredient:

Clobex uses Clobetasol Propionate as the active ingredient. Check out other Drugs and Companies using Clobetasol Propionate ingredient

Treatment:

Clobex is used for treating scalp psoriasis and moderate to severe plaque psoriasis.

Dosage:

Clobex is available in shampoo form for topical use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.05% SHAMPOO Prescription TOPICAL


Clobex Patent Expiration

Clobex is a drug owned by Galderma Laboratories Lp. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 24, 2018. Details of Clobex's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5990100 Composition and method for treatment of psoriasis
Mar, 2018

(6 years ago)

Expired
US5972920 Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders
Feb, 2018

(6 years ago)

Expired
US6106848 Topically applicable O/W emulsions having high glycol content and at least one biologically active agent
Sep, 2017

(7 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Clobex's patents.

Given below is the list of recent legal activities going on the following patents of Clobex.

Activity Date Patent Number
Patent litigations
Expire Patent 01 Jan, 2024 US8066975
Expire Patent 01 Jan, 2024 US8066976
Maintenance Fee Reminder Mailed 17 Jul, 2023 US8066975
Maintenance Fee Reminder Mailed 17 Jul, 2023 US8066976
Expire Patent 23 May, 2022 US7700081
Maintenance Fee Reminder Mailed 06 Dec, 2021 US7700081
Payment of Maintenance Fee, 8th Year, Large Entity 16 May, 2019 US8066975
Payment of Maintenance Fee, 8th Year, Large Entity 16 May, 2019 US8066976
Payment of Maintenance Fee, 8th Year, Large Entity 05 Oct, 2017 US7700081
Patent Issue Date Used in PTA Calculation 29 Nov, 2011 US8066975

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Clobex is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Clobex's family patents as well as insights into ongoing legal events on those patents.

Clobex's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Clobex's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 24, 2018 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Clobex Generics:

Clobetasol Propionate is the generic name for the brand Clobex. 34 different companies have already filed for the generic of Clobex, with Taro having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Clobex's generic

How can I launch a generic of Clobex before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Clobex's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Clobex's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Clobex -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
0.0005 27 Mar, 2006 1 04 Dec, 2008 22 Sep, 2017 Eligible
0.0005 29 Sep, 2008 1 16 Jun, 2011 24 Mar, 2018 Eligible
0.0005 09 Jan, 2008 1 07 Jun, 2011 17 Jun, 2019 Non-Forfeiture

Alternative Brands for Clobex

Clobex which is used for treating scalp psoriasis and moderate to severe plaque psoriasis., has several other brand drugs in the same treatment category and using the same active ingredient (Clobetasol Propionate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Primus Pharms
Impoyz

(uses Clobetasol Propionate)

Used for treating moderate to severe plaque psoriasis in patients 18 years of age or older.

Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Clobetasol Propionate. Given below is the list of those drugs and companies owning them.

Drug Owner Drug Name
Eyenovia
Clobetasol Propionate
Norvium Bioscience
Olux
Olux E


Apart from brand drugs containing the same ingredient, some generics have also been filed for Clobetasol Propionate, Clobex's active ingredient. Check the complete list of approved generic manufacturers for Clobex





About Clobex

Clobex is a drug owned by Galderma Laboratories Lp. It is used for treating scalp psoriasis and moderate to severe plaque psoriasis. Clobex uses Clobetasol Propionate as an active ingredient. Clobex was launched by Galderma Labs Lp in 2005.

Approval Date:

Clobex was approved by FDA for market use on 27 October, 2005.

Active Ingredient:

Clobex uses Clobetasol Propionate as the active ingredient. Check out other Drugs and Companies using Clobetasol Propionate ingredient

Treatment:

Clobex is used for treating scalp psoriasis and moderate to severe plaque psoriasis.

Dosage:

Clobex is available in lotion form for topical use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.05% LOTION Prescription TOPICAL